ClinicalTrials.gg
CompletedNCT07746739Updated Aug 10, 2026

Efficacy of Platelet Rich Plasma on Pelvic Floor Muscle Strength and Recurrence Rate in Pelvic Organ Prolapse Surgery

An interventional study of POP surgery adjunctive PRP and POP surgery adjunctive with placebo ( NaCl Injection) in Pelvic Organ Prolapse Vaginal Surgery, Pelvic Organ Prolapse and Platelet Rich Plasma Injection, sponsored by Andalas University. Completed at 1 site in Indonesia. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Andalas University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Aug 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Study summary

Pelvic organ prolapse (POP) is a common pelvic floor disorder associated with impaired quality of life and considerable postoperative recurrence following native tissue repair. Platelet-rich plasma (PRP) has emerged as a regenerative adjunct to improve tissue healing and surgical outcomes.

Objective: To evaluate the effect of adjuvant PRP on pelvic floor muscle A single-blind randomized controlled trial was conducted involving 40 women with stage II or higher POP who were randomly assigned to surgery with adjuvant PRP (n=20) or surgery alone (n=20). Pelvic floor muscle strength was assessed by perineometry, while anatomical outcomes were evaluated using the Pelvic Organ Prolapse Quantification (POP-Q) system 8 weeks postoperatively.

02

Conditions studied

  • Pelvic Organ Prolapse Vaginal Surgery
  • Pelvic Organ Prolapse
  • Platelet Rich Plasma Injection

Browse trials for

Keywords

  • pelvic organ prolapse
  • pelvic floor muscle strength
  • POP recurrence
  • prp injection
  • levatoa ani muscle tone
03

In context

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 337 interventional studies indexed under Pelvic Organ Prolapse.

Browse Pelvic Organ Prolapse studies →

Lead sponsor

Andalas University is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: women aged ≤65 years with stage II or higher pelvic organ prolapse (POP) who provided written to participate

Exclusion Criteria:a history of gynecologic , collagen vascular disease, hematological disorders, or diabetes mellitus.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    PRP Injection

    Participants in the intervention group underwent standard prolapse surgery with adjuvant platelet-rich plasma administration. The control group underwent identical surgical treatment without PRP. A five 5 ml PRP injection is injected in 1,5 cm below urethra in pubocervicalis fascia in anterior vaginal wall following POP surgery in intervention group. Meanwhile 5 ml NaCl injection were injected in the same location following POP surgery in control group

    Procedure: POP surgery adjunctive PRP

  • Placebo comparator
    Placebo injection

    in this arm patient who received standard operation procedure was given placebo injection

    Procedure: POP surgery adjunctive with placebo ( NaCl Injection)

Interventions

  • ProcedurePOP surgery adjunctive PRP

    In this RCT participants receive POP surgery with adjunctive PRP injection in anterior vaginal wall approximately 1,5 cm below urethra at Pubocervical Fascia. Pelvic organ prolapse quantification and assessment of Levator ani muscle tone by using Eden Q biofeedback tool before surgery and 8 weeks postoperative

  • ProcedurePOP surgery adjunctive with placebo ( NaCl Injection)

    During POP surgery placebo group receive NaCl injection in Pubocervicalis Fascia at 1,5 cm below urethra

06

What researchers measure

Primary outcomes

  1. Pelvic Floor Muscle Strength

    Pelvic Floor Muscle strength was assessed by using EDAN q biofeedback. The output were resting tone, quick contraction, contonous contraction and post resting tone.

    Time frame: From enrollment until post operative evaluation at 8 weeks

  2. Degree of Pelvic Organ Prolapse

    Degree of POP is measured by using POPQ assessment. Points Ba, C, and Bp are described degree of cystocele, uterine prolapse and rectocele respectively

    Time frame: From enrollment to the post operative follow up at 8 weeks

07

Study locations

1 site
  • M Djamil Hospital
    Padang, West Sumatera 25129, Indonesia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Mar 2026, 7 months.

Of 162 non-industry interventional studies with no phase under Pelvic Organ Prolapse, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's 7 months is below that.

Counting every sponsor, half of 179 studies reached it within 23 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2026
First posted
Aug 5, 2026
StartActual
Aug 25, 2025
Primary completionActual
Mar 30, 2026
CompletionActual
Apr 30, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07746739
Lead sponsor
Andalas University
Collaborators
Dr. M Djamil Hospital, Padang
Responsible party
Yulia Margaretta Sari (Head of Urogynecology Division, Andalas University) — Principal investigator
First posted
Aug 5, 2026
Start date
Aug 25, 2025
Primary completion
Mar 30, 2026
Completion
Apr 30, 2026
Last update
Aug 10, 2026

Study contacts

Yulia Margaretta Sari, MD
principal investigator · M Djamil Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion